Clinical Trials Browser

Phase 2 × Lymphoma, Follicular × ublituximab × Clear all

NCT04508647 2024-03-21

Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

Phase 2 Completed

4 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03828448 2023-07-24

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

Phase 2 Terminated

34 enrolled 2 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell